Sezary syndrome
MONDO:0017844Sezary syndrome (SS) is an aggressive form of cutaneous T-cell lymphoma characterized by a triad of erythroderma, lymphadenopathy and circulating atypical lymphocytes (Sezary cells).
Also known as: CTCL / Sezary syndrome, SC)zary syndrome, Sezary disease, Sezary lymphoma, Sezary syndrome, Sezary's disease, Sheehan Syndrome, Sézary lymphoma
3118 clinical trials for this condition and its sub-types, 45 tagged with Sezary syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New pill shows promise for rare skin cancer in early trial
Disease control OngoingThis early-phase trial tests a new drug called tulmimetostat (DZR123) in 24 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. Participants must have tried at least one prior treatment. The study aims to see if the drug is safe and tolerable, …
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill takes on tough lymphoma: early trial seeks tumor shrinkage
Disease control OngoingThis early-phase trial tests an oral drug called TLN-254 in about 50 adults with relapsed or refractory T-cell lymphoma. The main goal is to see if the drug can shrink tumors and how safe it is. Participants take the drug by mouth on a set schedule, and researchers will monitor r…
Phase 1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat skin cancers in early trial
Disease control OngoingThis early-stage trial tests a combination of two drugs, duvelisib and nivolumab, in 38 adults with advanced mycosis fungoides or Sezary syndrome (types of skin lymphoma). The goal is to find the safest dose and see if the drugs can shrink tumors. Duvelisib blocks certain enzymes…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Engineered donor cells take aim at tough blood cancers in early trial
Disease control PausedThis early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat skin cancer
Disease control PausedThis early-phase trial tests two drugs, mogamulizumab and brentuximab vedotin, given together to people with a rare type of skin lymphoma (CTCL or mycosis fungoides) that has not responded to prior treatment. The main goal is to see if the combination is safe and to find the best…
Phase 1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo targets rare skin cancer in small trial
Disease control OngoingThis study tests whether combining pembrolizumab (an immunotherapy) with gemcitabine (a chemotherapy drug) can shrink tumors in people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. The trial enrolled 14 adults who had already tried at least one …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Donor stem cell transplant shows promise for tough blood cancers
Disease control OngoingThis study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC